{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T03:49:57Z","timestamp":1726458597236},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health Microbicide Innovation Program","award":["8R21A1076967-02"],"award-info":[{"award-number":["8R21A1076967-02"]}]},{"name":"Small Business Innovative Research Program","award":["2R44A1067047-02"],"award-info":[{"award-number":["2R44A1067047-02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.antiviral.2011.10.013","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T22:16:45Z","timestamp":1319149005000},"page":"505-508","source":"Crossref","is-referenced-by-count":7,"title":["Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents"],"prefix":"10.1016","volume":"92","author":[{"given":"Tracy L.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Robert W.","family":"Buckheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.antiviral.2011.10.013_b0005","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.10.013_b0010","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.38.4.688","article-title":"Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro","volume":"38","author":"Baba","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.antiviral.2011.10.013_b0015","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2146\/ajhp100156","article-title":"Management of HIV infection in treatment-na\u00efve patients: a review of the most current recommendations","volume":"68","author":"Boyd","year":"2011","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.antiviral.2011.10.013_b0020","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.39.12.2718","article-title":"Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide","volume":"39","author":"Buckheit","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.10.013_b0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.45.2.393-400.2001","article-title":"SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency type 1 (HIV-1) that also inhibits HIV-2","volume":"45","author":"Buckheit","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2011.10.013_b0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/AAC.00972-07","article-title":"Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2","volume":"52","author":"Buckheit","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.antiviral.2011.10.013_b0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jama.283.3.381","article-title":"Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel","volume":"283","author":"Carpenter","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2011.10.013_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cbdv.200490012","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future","volume":"1","author":"De Clercq","year":"2004","journal-title":"Chem. Biodivers."},{"issue":"5","key":"10.1016\/j.antiviral.2011.10.013_b0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years","volume":"19","author":"De Clercq","year":"2009","journal-title":"Rev Med Virol."},{"key":"10.1016\/j.antiviral.2011.10.013_b0130","doi-asserted-by":"crossref","unstructured":"Deek, E.D.,Perry, C.M., 2010. Efavirenz\/emtricitabine\/tenofovir disoproxil fumarate single tablet regimen (Atripla\u00ae): a review of its use in the management of HIV infection. Drugs 70 (17), 2315\u201338.12.","DOI":"10.2165\/11203800-000000000-00000"},{"key":"10.1016\/j.antiviral.2011.10.013_b0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J","article-title":"Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia","volume":"18","author":"Foley","year":"1965","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.antiviral.2011.10.013_b0060","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00002030-200108170-00001","article-title":"Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B","volume":"15","author":"Grossman","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2011.10.013_b0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1742-4690-7-85","article-title":"Subtype \u2013 associated differences in HIV-1 reverse transcriptase affect the viral replication","volume":"7","author":"Iordanskiy","year":"2010","journal-title":"Retrovirology"},{"issue":"11","key":"10.1016\/j.antiviral.2011.10.013_b0140","article-title":"Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)","volume":"12","author":"Martinex-Cajas","year":"2009","journal-title":"J Intl AIDS Society"},{"key":"10.1016\/j.antiviral.2011.10.013_b0075","first-page":"CD004246","article-title":"A. Spaulding, G.W. Rutherford and N. Siegfried. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-na\u00efve individuals","volume":"12","author":"Mbuagbaw","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.antiviral.2011.10.013_b0080","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/aid.1987.3.283","article-title":"Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody","volume":"3","author":"Nara","year":"1987","journal-title":"AIDS Res. Hum Retrovir."},{"key":"10.1016\/j.antiviral.2011.10.013_b0145","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.antiviral.2011.10.013_b0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antivir Res."},{"key":"10.1016\/j.antiviral.2011.10.013_b0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/S0034-89102006000200023","article-title":"Worldwide molecular epidemiology of HIV","volume":"40","author":"Requejo","year":"2006","journal-title":"Rev Saude Publica"},{"issue":"4","key":"10.1016\/j.antiviral.2011.10.013_b0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/14787210.6.4.427","article-title":"Etravirine for the treatment of HIV infection","volume":"6","author":"Seminari","year":"2008","journal-title":"Expert Rev Anti Infect Ther."},{"key":"10.1016\/j.antiviral.2011.10.013_b0105","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1056\/NEJMra0706737","article-title":"The challenge of HIV-1 subtype diversity","volume":"358","author":"Taylor","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.antiviral.2011.10.013_b0110","unstructured":"UNAIDS\/WHO, 2009. AIDS epidemic update\/Revised HIV estimates: December 2009. UNAIDS (Joint United Nations Programme on HIV\/AIDS) and World Health Organization (WHO). UNAIDS, Geneva, Switzerland. http:\/\/data.unaids.org\/pub\/Report\/2009\/JC1700_Epi_Update_2009_en.pdf."},{"key":"10.1016\/j.antiviral.2011.10.013_b0115","doi-asserted-by":"crossref","unstructured":"Yazdanpanah, Y., D. Sissoko, M. Egger, Y. Mouton, M. Zwahlen and G. Chene, Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ, doi:10.1136. Jan.2004.","DOI":"10.1136\/bmj.37995.435787.A6"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211004736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211004736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T04:23:38Z","timestamp":1560831818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211004736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0166354211004736"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.10.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}